NCT06008808View on ClinicalTrials.gov

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

PHASE1RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

September 9, 2026

Study Completion Date

December 11, 2026

Conditions
Graft Vs Host DiseaseGraft-versus-host-diseaseGraft Versus Host Disease
Interventions
DRUG

Ruxolitinib

Ruxolitinib is provided by Incyte Corporation.

DRUG

Abatacept

Abatacept is commercially available.

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Washington University School of Medicine

OTHER